CUE Cue Biopharma Inc
1,290
$1.74
$0.175
(9.14%)
| Watchers | 1,290 |
| 52-Wk Low | $1.30 |
| 52-Wk High | $4.89 |
| Market Cap | $84.64M |
| Volume | 449,013.00 |
| 52-Wk High | $4.89 |
| 52-Wk Low | $1.30 |
Forecasting The Future: 4 Analyst Projections For Cue BiopharmaBenzinga • about 1 month ago
Latest Ratings for CUE
DateFirmActionFromTo Nov 2020BerenbergInitiates Coverage OnBuy May 2020StifelMaintainsBuy May 2020OppenheimerMaintainsOutperform
View More Analyst Ratings for CUE...
Share to Feed
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Navalign LLC bought a new stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities Exchange...
Jefferies Financial Group assumed coverage on shares of Cue Biopharma (NASDAQ:CUE Free Report) in a research report released on Wednesday, MarketBeat reports. The firm issued a buy rating and...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Sigma Planning Corp increased its holdings in Cue Biopharma, Inc. (NASDAQ:CUE Free Report) by 8.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...
Cue Biopharma, Inc. (NASDAQ:CUE Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000...
Cue Biopharma, Inc. (NASDAQ:CUE Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 3,420,000 shares, an increase of...